Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 25;6(2):590-599.
doi: 10.1182/bloodadvances.2021004970.

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

Affiliations

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

Pier Luigi Zinzani et al. Blood Adv. .

Abstract

KEYNOTE-204 (NCT02684292) demonstrated a progression-free survival advantage for pembrolizumab over brentuximab vedotin (BV) in patients who had relapsed or refractory classical Hodgkin lymphoma (R/R cHL) following, or who were ineligible for, autologous stem cell transplantation (ASCT). Health-related quality of life (HRQoL), measured by patient-reported outcomes (PROs) from KEYNOTE-204, are reported from patients who received ≥1 dose of study treatment and completed ≥1 PRO assessment. The EORTC QoL Questionnaire Core 30 (QLQ-C30) and EuroQoL EQ-5D were administered at baseline, every 6 weeks until week 24, and every 12 weeks thereafter. Prespecified end points included least squares mean (LSM) changes from baseline to week 24 and time to true deterioration (TTD; ≥10-point decline from baseline). Comparisons were evaluated using 2-sided P values uncontrolled for multiplicity. High compliance at baseline (>90%) and through week 24 (>80%) was demonstrated across treatment groups (PRO analysis set: pembrolizumab, n = 146; BV, n = 150). The EORTC QLQ-C30 global health status (GHS)/quality of life (QoL) score improved from baseline to week 24 on pembrolizumab and worsened on BV and demonstrated significant LSM differences at 24 weeks (GHS/QoL: 8.60 [95% confidence interval, 3.89-13.31]; P = .0004). Significant improvements were observed in each QLQ-C30 domain except emotional and cognitive functioning. Compared with BV, pembrolizumab prolonged TTD for GHS/QoL (hazard ratio, 0.40 [95% CI, 0.22-0.74]; P = .003) and each QLQ-C30 domain except cognitive functioning. In conclusion, pembrolizumab demonstrated overall improvements in PROs of HRQoL measures over BV in the KEYNOTE-204 study. These data and previously reported efficacy results support pembrolizumab as the preferred treatment option for patients with R/R cHL who are ineligible for or experience relapse after ASCT.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
QLQ-C30 LSM score change from baseline to week 24.
Figure 2.
Figure 2.
(A–F) QLQ-C30 empirical mean change from baseline over 48 weeks. SE, standard error.
Figure 3.
Figure 3.
Improved/stable/worsening of QLQ-C30 scores at week 24. Pembro, pembrolizumab.
Figure 4.
Figure 4.
Kaplan-Meier estimates of time to true deterioration. (A) QLQ-C30 global health status/QoL. (B) QLQ-C30 physical functioning. (C) QLQ-C30 role functioning. (D) QLQ-C30 emotional functioning. (E) QLQ-C30 cognitive functioning. (F) QLQ-C30 social functioning. Time to true deterioration is defined as the time to first onset of 10 or more decrease from baseline with confirmation under right-censoring rule (the last observation). *Two-sided P value based on log-rank test.

References

    1. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol. 2004;124(5):645-652. - PubMed
    1. Villa D, Seshadri T, Puig N, et al. . Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin’s lymphoma resistant to platinum-containing first-line salvage chemotherapy. Haematologica. 2012;97(5):751-757. - PMC - PubMed
    1. Santoro A, Mazza R, Pulsoni A, et al. . Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2020;4(1):136-140. - PMC - PubMed
    1. Goodman KA, Riedel E, Serrano V, Gulati S, Moskowitz CH, Yahalom J. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin’s lymphoma. J Clin Oncol. 2008;26(32):5240-5247. - PubMed
    1. Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Silver Spring, MD: US Department of Health and Human Services. 2009 - PMC - PubMed

Publication types

MeSH terms